<DOC>
	<DOCNO>NCT00080223</DOCNO>
	<brief_summary>To assess safety treatment pirfenidone ( 3600 mg/d ) patient pulmonary fibrosis/idiopathic pulmonary fibrosis ( PF/IPF ) .</brief_summary>
	<brief_title>Safety Study Oral Pirfenidone Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>This study design rollover study collectively include safety data various previous study . In addition , InterMune also initiate Early Access Program make pirfenidone available limited number patient idiopathic pulmonary fibrosis United States . This program also conduct protocol . Registration patient document IPF close October 2005 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>General Able understand sign inform consent form Understand importance adherence study treatment study protocol , include concomitant medication restriction , throughout study period Patients must willing travel approve regional center studyrelated visit RollOver Criteria : Entry study rollover complete Criteria Early Access Program patient : Clinical symptom consistent IPF ≥3 month duration Age 40 85 , inclusive At time registration National Organization Rare Disorders ( NORD ) , patient IPF must percent predict forced vital capacity ( FVC ) ≥50 % , percent predict carbon monoxide diffuse capacity ( DLCO ) ≥35 % At time enrollment PIPF002 , ( screening/baseline visit ) percent predict FVC must ≥45 % , percent predict DLCO must ≥30 % Highresolution compute tomographic scan ( HRCT ) show definite IPF . For patient surgical lung biopsy show definite probable usual interstitial pneumonia ( UIP ) , HRCT criterion probable IPF sufficient For patient age &lt; 50 year : open videoassisted thoracoscopic ( VATS ) lung biopsy show definite probable UIP . In addition , feature support alternative diagnosis transbronchial biopsy bronchoalveolar lavage perform For patient age ≥50 year : least one follow diagnostic finding well absence feature specimens result procedure support alternative diagnosis : 1 ) Open VATS lung biopsy show definite probable UIP ; 2 ) Transbronchial biopsy show feature support alternative diagnosis ; 3 ) Bronchoalveolar lavage ( BAL ) show feature support alternative diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pulmonary fibrosis</keyword>
	<keyword>respiratory disease</keyword>
</DOC>